ARTICLE | Financial News
Arch Oncology raises $50M series B to develop anti-CD47 mAb
March 25, 2019 12:02 PM UTC
Backed by new investor Lightchain, Arch Oncology raised $50 million in a series B round to enable the company to advance its anti-CD47 mAb, AO-176, which is in a Phase I trial to treat solid tumors.
President and CEO of Arch Oncology Inc. (Brisbane, Calif.) Julie Cherrington told BioCentury that data from the trial are expected by year end...